These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 17005381)

  • 41. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy.
    Matsuo M
    IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon.
    Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M
    Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human artificial chromosomes for Duchenne muscular dystrophy and beyond: challenges and hopes.
    Tedesco FS
    Chromosome Res; 2015 Feb; 23(1):135-41. PubMed ID: 25596829
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy.
    Heemskerk H; de Winter CL; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
    Ann N Y Acad Sci; 2009 Sep; 1175():71-9. PubMed ID: 19796079
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy.
    Rodino-Klapac LR; Janssen PM; Montgomery CL; Coley BD; Chicoine LG; Clark KR; Mendell JR
    J Transl Med; 2007 Sep; 5():45. PubMed ID: 17892583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
    Athanasopoulos T; Graham IR; Foster H; Dickson G
    Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oligonucleotide-mediated gene editing for neuromuscular disorders.
    Bertoni C
    Acta Myol; 2005 Dec; 24(3):194-201. PubMed ID: 16629053
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A non-viral vector for potential DMD gene therapy study by targeting a minidystrophin-GFP fusion gene into the hrDNA locus.
    Yang J; Liu X; Yu J; Sheng L; Shi Y; Li Z; Hu Y; Xue J; Wu L; Liang Y; Xia J; Liang D
    Acta Biochim Biophys Sin (Shanghai); 2009 Dec; 41(12):1053-60. PubMed ID: 20011980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progress toward gene therapy of Duchenne muscular dystrophy.
    Hartigan-O'Connor D; Chamberlain JS
    Semin Neurol; 1999; 19(3):323-32. PubMed ID: 12194388
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Duchenne and Becker muscular dystrophies.
    Flanigan KM
    Neurol Clin; 2014 Aug; 32(3):671-88, viii. PubMed ID: 25037084
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Gene-specific treatment approaches in muscle diseases].
    Lehmann Urban D; Schneider I
    Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neurology Care, Diagnostics, and Emerging Therapies of the Patient With Duchenne Muscular Dystrophy.
    Leigh F; Ferlini A; Biggar D; Bushby K; Finkel R; Morgenroth LP; Wagner KR
    Pediatrics; 2018 Oct; 142(Suppl 2):S5-S16. PubMed ID: 30275245
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Postnatal gene therapy for neuromuscular diseases - opportunities and limitations.
    Kirschner J
    J Perinat Med; 2021 Oct; 49(8):1011-1015. PubMed ID: 34499826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The progress of AAV-mediated gene therapy in neuromuscular disorders.
    Aguti S; Malerba A; Zhou H
    Expert Opin Biol Ther; 2018 Jun; 18(6):681-693. PubMed ID: 29781327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The basic concept of therapeutic approaches for DMD].
    Amthor H
    Arch Pediatr; 2015 Dec; 22(12 Suppl 1):12S63-8. PubMed ID: 26773589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies.
    Benedetti S; Hoshiya H; Tedesco FS
    FEBS J; 2013 Sep; 280(17):4263-80. PubMed ID: 23387802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gene Therapy for Duchenne Muscular Dystrophy: Unlocking the Opportunities in Countries in the Middle East and Beyond.
    Elbashir H; Fathalla W; Mundada V; Iqbal M; Al Tawari AA; Chandratre S; Bastaki L; Romany I; Ismayl O; Abou Tayoun A
    J Neuromuscul Dis; 2022; 9(6):787-801. PubMed ID: 36245386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Duchenne muscular dystrophy in the Western Cape, South Africa: Where do we come from and where are we going?
    Esterhuizen AI; Greenberg LJ; Ballo R; Goliath RG; Wilmshurst JM
    S Afr Med J; 2016 May; 106(6 Suppl 1):S67-71. PubMed ID: 27245531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.